Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSCIS-ON.
Allanore Y, Vonk MC, Distler O, Azuma A, Mayes MD, Gahlemann M, James A, Kohlbrenner V, Alves M, Khanna D, Highland KB; SENSCIS-ON trial investigators. Allanore Y, et al. Among authors: kohlbrenner v. Ann Rheum Dis. 2022 Dec;81(12):1722-1729. doi: 10.1136/ard-2022-222564. Epub 2022 Aug 16. Ann Rheum Dis. 2022. PMID: 35973804 Free PMC article.
Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial.
Seibold JR, Maher TM, Highland KB, Assassi S, Azuma A, Hummers LK, Costabel U, von Wangenheim U, Kohlbrenner V, Gahlemann M, Alves M, Distler O; SENSCIS trial investigators. Seibold JR, et al. Among authors: kohlbrenner v. Ann Rheum Dis. 2020 Nov;79(11):1478-1484. doi: 10.1136/annrheumdis-2020-217331. Epub 2020 Aug 5. Ann Rheum Dis. 2020. PMID: 32759258 Free PMC article. Clinical Trial.
Disease frequency, patient characteristics, comorbidity outcomes and immunosuppressive therapy in systemic sclerosis and systemic sclerosis-associated interstitial lung disease: a US cohort study.
Li Q, Wallace L, Patnaik P, Alves M, Gahlemann M, Kohlbrenner V, Raabe C, Wang JR, Garry EM. Li Q, et al. Among authors: kohlbrenner v. Rheumatology (Oxford). 2021 Apr 6;60(4):1915-1925. doi: 10.1093/rheumatology/keaa547. Rheumatology (Oxford). 2021. PMID: 33155024 Free PMC article.
Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial.
Gathe J, Cooper DA, Farthing C, Jayaweera D, Norris D, Pierone G Jr, Steinhart CR, Trottier B, Walmsley SL, Workman C, Mukwaya G, Kohlbrenner V, Dohnanyi C, McCallister S, Mayers D; RESIST-1 Study Group. Gathe J, et al. Among authors: kohlbrenner v. Clin Infect Dis. 2006 Nov 15;43(10):1337-46. doi: 10.1086/508353. Epub 2006 Oct 17. Clin Infect Dis. 2006. PMID: 17051503 Clinical Trial.
18 results